Gyala

Gyala Therapeutics has initiated a Phase I/IIa clinical trial of its investigational CAR-T cell therapy, GYA01, after receiving authorization from Spain's Agency of Medicines and Medical Devices (AEMPS). The clinical-stage biotechnology company is advanci

Gyala Therapeutics, a clinical-stage biotechnology company developing innovative cell therapies for hematologic malignancies, today announced the initiation of a Phase I/IIa clinical trial of GYA01 following authorization from the Spanish Agency of Medici

Gyala Therapeutics, a biotechnology company dedicated to creating next-generation treatments for blood cancers, has shared encouraging results from early studies of its new CAR-T therapy, GYA01. This therapy is designed to attack a protein called CD84, wh

Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukaemias

Gyala Therapeutics, ein Biotechnologieunternehmen, das Immuntherapien der nächsten Generation für Blutkrebs entwickelt, gab die Veröffentlichung präklinischer Ergebnisse bekannt, die die Wirksamkeit seiner CAR-T-Therapie GYA01 bei Leukämie belegen. Die St

Gyala Therapeutics, a biotechnology company developing next-generation immunotherapies for blood cancers, announced the publication of preclinical results demonstrating the efficacy of its CAR-T therapy, GYA01, in Leukemia. The study is the first to show

/PRNewswire/ -- Gyala Therapeutics, a biotechnology company developing next-generation immunotherapies for blood cancers, announced the publication of...